Form 4 Filing for BridgeBio Pharma, Inc.

This filing reports transactions by Ali J. Satvat, a director at BridgeBio Pharma, Inc. On June 22, 2026, Satvat acquired 3,990 shares of Common Stock and 5,277 Stock Options. The RSUs vest on June 22, 2027, subject to continued service. The filing also includes a Power of Attorney document, appointing attorneys-in-fact to handle SEC filings related to beneficial ownership and changes in securities holdings.